Gevorg Tamamyan: Waiting to see promising bot/bal results from our lung cancer trial
Gevorg Tamamyan posted on LinkedIn:
“Just saw the presentation from ESMO GI Annual Congress and the outstanding results after neoadjuvant botensilimab and balstilimab in colorectal cancer. The images are from a 40-year-old female with Stage 3 MSS Colorectal Cancer (CRC), after 7 weeks with BOT/BAL therapy – complete response (100% tumor reduction)! Congratulations to all the great team of investigators – Pashtoon Kasi and colleagues and of course, wonderful Agenus team!
Waiting for similar results also from our lung cancer trial with BOT/BAL (NCT06322108), conducted by our Immune Oncology Research Institute.
We need to hurry up, because cancer and patients cannot wait!”
Source: Gevorg Tamamyan/LinkedIn
Gevorg Tamamyan is the Editor-in-chief of OncoDaily, President-Elect of SIOP Asia Continental Branch and Pediatric Oncology East and Mediterranean (POEM) Group, and the CEO of the Immune Oncology Research Institute (IMMONC).
He is a Co-Founder and Board Member of the Armenian Association of Hematology and Oncology, City of Smile Charitable Foundation, Co-Founder and Chairman of the Board of the Institute of Cancer and Crisis, the Former President of the Harvard Club of Armenia.